IBOGF (Universal Ibogaine) Accounts Payable & Accrued Expense: $0.55 Mil (As of Apr. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Universal Ibogaine Accounts Payable & Accrued Expense?

Universal Ibogaine IBOGF +9.30% Accounts Payable & Accrued Expense is $0.55 Mil as of Apr. 2025.

Universal Ibogaine's quarterly accounts payable & accrued expense declined from Oct. 2024 ($0.57 Mil) to Jan. 2025 ($0.51 Mil) but then increased from Jan. 2025 ($0.51 Mil) to Apr. 2025 ($0.55 Mil).

Universal Ibogaine's annual accounts payable & accrued expense increased from Jul. 2022 ($0.36 Mil) to Jul. 2023 ($0.66 Mil) but then declined from Jul. 2023 ($0.66 Mil) to Jul. 2024 ($0.53 Mil).

Universal Ibogaine Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Accounts Payable & Accrued Expense Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 0.02 0.06 0.36 0.66 0.53

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.53 0.57 0.51 0.55

Universal Ibogaine Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $0.55 Mil mean?
Universal Ibogaine (IBOGF) has a Accounts Payable & Accrued Expense of $0.55 Mil as of Apr. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's Accounts Payable & Accrued Expense too high?
Universal Ibogaine's current Accounts Payable & Accrued Expense is $0.55 Mil.
How does Universal Ibogaine's Accounts Payable & Accrued Expense compare to LABT and CALC?
Universal Ibogaine's Accounts Payable & Accrued Expense of $0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current Accounts Payable & Accrued Expense is $0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Accounts Payable & Accrued Expense of $0.55 Mil. The current Accounts Payable & Accrued Expense is $0.55 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Accounts Payable & Accrued Expense is $0.55 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.